1372 - Comparison of Healthcare Resource Utilization (HRU) Among Adult Patients Treated with Omadacycline (OMC) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) or Community-Acquired Bacterial Pneumonia (CABP) in the 30 Day Pre- and Post-OMC Prescription (Rx)

Pts who received ≥1 OMC outpatient Rx from a large US claims database (10/2018-9/2020) were identified. Pts were classified as ABSSSI or CABP cohort based on presence of ICD-10 code near (-90 d to +30 d) OMC Rx. Within each diagnosis, pts were classified as complicated if any of the following infections were identified in the pre-period (-90 d to + 5 d) (ABSSSI: osteomyelitis (OST), sepsis/bacteremia (S/B), endocarditis, implant, necrotizing fasciitis, meningitis; CABP: severe pneumonia, lung abscess, S/B, endocarditis, meningitis). Risk of inpatient admissions (IP), ED visits, outpatient visits (OP) were compared between the following 2 periods: 30 days pre- and 30-days post-OMC Rx.

Results: During study period, 258 OMC outpatient Rx met inclusion criteria: 189 were ABSSSI and 69 were CABP.  Among the 189 ABSSSI pts, 83 were complicated. Most common ABSSSI complicated were OST (53%), S/B (33%), and implant infection (21%). Among the 69 CABP pts, 20 were COM. Most common CABP complicated were S/B (80%) and severe pneumonia (25%).  Comparison of HRU in the 30 days pre- to the 30-day post-OMC Rx period are shown in Tables 1 and 2.  Among complicated ABSSSI pts, IP decreased by 38% (41% vs 25%; p< 0.05) while ED visits and OP were similar. Among non- complicated ABSSSI pts, IP decreased by 61% (17% vs 7%; p< 0.05), ED visits decreased by 88% (16% vs 2%; p< 0.01) while OP were similar. Among complicated CABP pts, IP decreased by 75% (80% vs 20%; p< 0.01), ED decreased by 100% (40% vs 0%; p< 0.001) while OP were similar.  Among non- complicated CABP pts, IP decreased by 75% (33% vs 8%; p< 0.01), while ED visits and OP were similar. Table 1. Comparison of HRU in the 30-day pre-OMC Rx vs 30-day post-OMC Rx period among ABSSSI pts
Table 2. Comparison of HRU in the 30-day pre-OMC Rx vs 30-day post-OMC Rx period among CABP pts


Conclusion:

This study provided the first real world characterization of pts treated with OMC for ABSSSI or CABP.  Patients who received OMC had lower HRU in the 30-days post- OMC Rx period relative to the 30-day pre-OMC Rx period.